Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum

Pawan Bhatnagar, K. Bailey Freund*, Richard F. Spaide, James M. Klancnik, Michael J. Cooney, Ivan Ho, Howard F. Fine, Lawrence A. Yannuzzi

*Corresponding author for this work

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

PURPOSE: To determine the results of intravitreal bevacizumab injections for the management of choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE)-associated angioid streaks. METHODS: A consecutive series of patients with PXE and CNV were managed with intravitreal bevacizumab injection (1.25 mg per 0.05 cc). The main outcome measures were visual acuity and greatest lesion height as measured by optical coherence tomography (OCT). RESULTS: Nine eyes of nine consecutive patients received intravitreal bevacizumab (1.25 mg/0.05 mL) injections. The mean follow-up time was 6 months, during which eyes received an average of 1.8 injections. The baseline visual acuity was a mean of 20/368 and improved to 20/289 at the last visit (P = 0.056). Visual acuity either improved or stabilized in all 9 eyes (100%). Serial OCT measurements in 8 eyes showed a mean of 353 μm at baseline, which decreased to 201 μm at the last visit (P = 0.012). No complications were noted. CONCLUSIONS: These short-term results support the use of intravitreal bevacizumab for the management of CNV in patients with PXE. Continued experience with intravitreal bevacizumab in this population will help establish its longer-term efficacy and better define the potential need for serial injections to maintain these results.

Original languageEnglish
Pages (from-to)897-902
Number of pages6
JournalRetina
Volume27
Issue number7
DOIs
Publication statusPublished - Sep 2007

Keywords

  • Angioid streaks
  • Avastin
  • Bevacizumab
  • Choroidal neovascularization
  • CNV
  • Grönblad-Strandberg syndrome
  • Pseudoxanthoma elasticum
  • PXE

Fingerprint Dive into the research topics of 'Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum'. Together they form a unique fingerprint.

Cite this